Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 24, 2026

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

View original at globenewswire.com
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cance…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BNT326/YL202 showed antitumor activity and favorable safety profile in advanced or metastatic NSCLC patients who progressed after standard of care therapy

    60% confidence

  • Pumitamig plus chemotherapy showed encouraging preliminary antitumor activity and survival outcomes with manageable tolerability profile as first-line therapy in extensive-stage small cell lung cancer

    60% confidence

  • Gotistobart showed a 54% reduction in the risk of death compared with standard of care chemotherapy in squamous NSCLC patients who progressed on prior immunotherapy plus chemotherapy

    60% confidence

  • BioNTech continues to advance differentiated treatment approaches across lung cancer settings while building clinical evidence to guide further development

    60% confidence

  • BioNTech aims to offer patients with lung cancer transformative treatment options that help provide meaningful long-term benefit across all stages of the disease

    60% confidence

  • The data presented at ELCC 2026 further define the potential of BioNTech's late-stage portfolio in lung cancer

    60% confidence

Data points we hold from this source

BioNTech SE · ongoing phase3 trials4 trials
BioNTech SE · ongoing clinical trials16 trials
BioNTech SE · ongoing novel novel combination trials5 trials

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer — Source | Via News | Finance Via News